PEARLS OF LABORATORY MEDICINE

IV. Direct Oral (DOACs): Impact & Interference of DOACs on Testing Robert (Bob) Gosselin, CLS Hemostasis & Thrombosis Center, University of California, Davis Health System Dorothy (Dot) Adcock, MD Chief Medical Officer, Laboratory Corporation of America

DOI: 10.15428/CCTC.2020.323824

© Clinical Chemistry This session is a combined effort between the American Association for Clinical Chemistry (AACC) and the North American Specialized Coagulation Laboratory Association (NASCOLA)

2 DOACs: New Consideration

Dabigatran is an oral direct inhibitor that inhibits free and bound thrombin

Apixaban, betrixaban, edoxaban and rivaroxaban are oral direct anti- Xa drugs that inhibit both free and bound factor activated FX (FXa)

DOACs have varying performance characteristics when assessing pharmacodynamics or pharmacokinetics using global or specific assays.

As DOACs are target specific, these drugs may impact coagulation assays and likely lead to erroneous result interpretation and potential patient mismanagement

3 DOACs: Considerations

• Will clot-based methods be affected by DOACs • Will non-clot-based methods be affected by DOACs • Will collection of trough samples sufficiently mitigate any DOAC interference • Are there alternative strategies for while on DOACs

4 Clot based methods for coagulation 1. Screening tests 1. PT/INR and APTT 2. Mixing studies 2. Factor assays • Factors II, V, VII and X – PT based assays • Factors VIII, IX, XI, XII and contact factors – APTT based assays • Inhibitor assays • 3. Thrombophilia related testing • Antithrombin activity • Lupus (different methods) • Protein C • Protein S • Activated Protein C Resistance 4. Others , ecarin clotting time, reptilase clotting time 5 Factor Assays – One stage Assays1 PT or APTT Dil Patient sample + Factor Deficient plasma Clot time

1. Clot time is inversely 120 Figure modified from reference 1

proportional to factor activity 100 2. A calibration curve will provide 80 a relationship between factor activity and clot time 60 3. Factor activity is extrapolated 40 Factor activity, % activity, Factor FII from calibration curve based 20 on obtained clot time from FVIII 0 sample 0 100 200 300 400 500 600 Dabigatran, ng/mL Caution when measuring factor activity in DOAC treated patients as this may lead to misdiagnosis and mismanagement

This caution also applies to clot-based inhibitor studies (e.g. Bethesda assay) 6 Fibrinogen and Thrombin time2

Fibrinogen Clotting time Patient sample, diluted Clotting time inversely High conc Thrombin proportional to FBG level

Thrombin time 3.50 Figure modified from reference 2 Patient sample, neat or diluted Clotting time 3.25 Low conc Thrombin 3.00 2.75 2.50 2.25 As dabigatran inhibits thrombin, its 2.00 1.75 presence will prolong clotting times 1.50 Fibrinogen, IU/ml 1.25 1.00 0 50 100 150 200 250 300 350 400 450 500 550 Dabigatran level, ng/ml

300.0 Anti-Xa DOACs do not affect 250.0 200.0 either test 150.0

100.0

Thrombin time, s 50.0 0.0 7 0 50 100 150 200 Dabigatran level, ng/ml Protein C testing1,3

Protein C in patient plasma Protac® + Activated protein C (APC) PC DP

APTT APC inhibition of factor VIIIa and Va

Prolonged clotting: prolongation proportional to PC present DOACs may prolong the APTT, which may Alternatively, chromogenic protein C is not cause false increase in Protein C affected by DOACs

Apixaban Dabigatran Rivaroxaban Dabigatran Rivaroxaban

200 200

180 180

160 160

140 140

120 120

Protac Protein C, % 100 100 Chromogenic Protein C, % 80 80 0 100 200 300 400 500 600 0 100 200 300 400 500 600 DOAC concentration, ng/mL DOAC concentration, ng/mL 8 Protein S testing1,3 Activated Protein C Protein S in patient + PS DP Protein S activation plasma

Bovine Va or RVVT activated Xa

Inhibition of factor Va

Prolonged clotting: prolongation proportional to PS present DOACs – Increase clotting time, therefore Alternatively, free protein S by latex falsely increasing PS result immunoassay is not affected by DOACs 200

200 Apixaban Rivaroxaban 180 180 Dabigatran Edoxaban 160 160 140 140

120 120 Free Protein S, %

100 100 Clottable Clottable protein % S,

80 80 0 100 200 300 400 500 600 0 100 200 300 400 500 600 DOAC concentration, ng/mL Dabigatran, ng/mL 9 Activated Protein C Resistance (APCR)1,3

Clotting time, s Patient sample APTT + APC APTT APCR Ratio: ______APTT Patient sample Clotting time, s APTT + APC Ratios >2.0 = negative APCR

DOACs – Increase clotting time may 3.8 result in false negative APCR 3.6 Dabigatran 3.4 3.2 Rivaroxaban EQA reports have also indicated 3.0 DOAC false positive APCR 2.8 2.6 APCR Ratio APCR 2.4 Alternatively genetic testing could 2.2 2.0 be performed, with caveat that 0 200 400 600 DOAC concentration, ng/mL unusual APCR mutations may be missed

10 Testing1,3,4 DOACs – Increase DRVVT RVVT1 Patient sample Clotting time, s RVVT1 clotting time, may >1.2 = LA RVVT2 RVVT2 falsely indicate LA Clotting time, s Patient sample Anti-Xa DOACs do Hexagonal phase not affect hexagonal APTT phase LA testing Patient sample Clotting time, s If PE APTT is >8s APTT shorter than APTT Clotting time, s Dabigatran false

Patient sample + PE positive LA at higher concentrations

2.00 12

10 1.80 Rivaroxaban 8 Apixaban 1.60 Siemens LA 6 Edoxaban ratio Dabigatran 1.40 4 DRVVT Ratio

1.20 2 Hexagonal phase difference,s 1.00 0 0 100 200 300 400 500 600 0 100 200 300 400 500 600 Rivaroxaban, ng/mL DOAC concentration, ng/mL 11 Advantage of Lupus Anticoagulant Testing Interference5

Because of linear dose dependent response for LA2 reagent to DOACs, it has been proposed as a method for DOAC quantitation

700 DOAC Cals source B: R2 = 0.8534 600 Figure modified from reference 5 500

400

300

200 DOAC Cals source A: R2 = 0.8775

100 Rivaroxaban by DRVVT, ng/ml DRVVT,Rivaroxaban by 0 0 100 200 300 400 500 600 700 800 900 Rivaroxaban by LC-MS/MS, ng/ml

However, lower limit of quantitation may not be sufficiently adequate

12 Chromogenic methods

Methods typically are two stage assays 1. Sample mixed with activated factor 2. Addition of specific substrate

Example: Antithrombin activity

Patient AT + FXaFIIa + [AT + Hep + FxaFIIa ] + FXaFIIa

Substrate pNA Peptide

13 Representative DOAC interference on chromogenic assay1,3

Apixaban Edoxaban Rivaroxban Dabigatran

150

140

130 Antithrombin activity using 120 factor Xa substrate

110

FXa Antithrombin method, % 100

90 0 100 200 300 400 500 600 DOAC concentration, ng/mL

14 Common Chromogenic coagulation methods 6,7

Test Factor II or X DOAC affect dependent Factor VIII Yes Yes Factor IX Yes Yes Factor X Yes Anti-Xa DOAC Antithrombin Yes Yes Protein C No No Plasminogen No No Alpha-2-antiplasmin No No Anti-Xa Yes Anti-Xa DOAC Ecarin Yes Anti-IIa DOAC

15 Test methods not affected by DOACs6-8

Latex immunoassays: D-dimer, VWF, Protein S, HIT ELISA methods: D-dimer, Protein C, Protein S, HIT Agglutination methods: monomer, VWF:RCo function testing (most)

Esoteric Tests that may be affected by DOACs

Thrombin based platelet aggregation Thrombin activatable inhibitor May alter fibrinolysis assays

16 Are trough collections adequate to minimize DOAC interference?6

Dabigatran Apixaban Betrixaban Edoxaban Rivaroxaban Trough levels yellow Test Bias (35 – 95ng/mL) (22 –177ng/mL) (12ng/mL) (10 – 39ng/mL) (6 – 239ng/mL)

Antithrombin-IIa method False ↑ ~25 No effect No effect No effect No effect

Antithrombin-Xa method False ↑ No effect ~40 - 110 No effect ~120 - 270 ~100 - 130

Protein C-clot based False ↑ ~25 >750 Unknown ~280 ~22

Protein C - chromogenic -- No effect No effect No effect No effect No effect

Protein S – activity False ↑ ~25 ~470 ~30 ~270 ~220

Protein S - antigen -- No effect No effect No effect No effect No effect

LA Screen ↑ ~25 ~80 – 110 ~10 ~20 – 35 ~10-30

LA Confirm ↑ ~25 ~80 ~10 ~20 ~20 – 30

LA Ratio False ↑ ~25 ~200 - >750 ~50 ~30 - >500 ~10 - >720

Biased APCR ~25 – 200 >740 Unknown >300 >300 Ratios# Method and reagent dependent Minimizing DOAC interference?7,9,10

1. Selecting tests that are not affected by DOACs 2. Use of ex-vivo DOAC neutralizing products: • DOAC-Stop • DOAC-Remove • Filters

Note of caution: No ex-vivo neutralizing product is currently FDA-approved for use Neutralizing products are not interchangeable Some products have some degree of inducing coagulation Variable plasma volume recovery

18 Summary: DOACs and interference with coagulation testing

• Clot-based methods are affected by DOACs Mostly true

• Non-clot-based methods are not affected by Mostly true DOACs

• Collection of trough samples will sufficiently Cautiously false mitigate any DOAC interference

• Alternative strategies for testing while on DOACs Consider alternative methods or DOAC neutralizing techniques

19 References

1. Adcock DM, Gosselin RC, Kitchen S, Dwyre DM. The Effect of Dabigatran on Select Specialty Coagulation Assays. Am J Clin Pathol 2013; 139:102-09. 2. Dager WE, Gosselin RC, Kitchen S, Dwyre D. Dabigatran effects on the international normalized ratio, activated partial thromboplastin time, thrombin time, and fibrinogen: a multicenter, in vitro study. Ann Pharmacother. 2012;46(12):1627-36. doi: 10.1345/aph.1R179. 3. Gosselin R, Grant RP, Adcock DM. Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays. Int J Lab Hematol. 2016;38(5):505-13. doi: 10.1111/ijlh.12528 4. Kim YA, Gosselin R, Van Cott EM. The effects of dabigatran on lupus anticoagulant, diluted plasma thrombin time, and other specialized coagulation assays. Int J Lab Hematol. 2015;37(4):e81-4. doi: 10.1111/ijlh.12319. 5. Gosselin RC, Francart SJ, Hawes EM, Moll S, Adcock-Funk D. Comparison of Anti-Xa and DRVVT assays in quantifying drug levels in patients taking therapeutic doses of rivaroxaban. Arch Pathol Lab Med 2014; 138:1680- 1684. 6. Gosselin RC, Adcock DM, Douxfils J. An update on laboratory assessment for direct oral anticoagulants (DOACs). Int J Lab Hematol. 2019;41 Suppl 1:33-39. doi: 10.1111/ijlh.12992. 7. Gosselin RC, Adcock DM, Bates SM, Douxfils J, et al. International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants. Thromb Haemost. 2018;118(3):437-450. doi:10.1055/s-0038-1627480. 8. Bonar R, Favaloro EJ, Mohammed S, Ahuja M, Pasalic L, Sioufi J, Marsden K. The effect of the direct factor Xa inhibitors apixaban and rivaroxaban on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples. Pathology. 2016;48(1):60-71. 9. Exner T, Ahuja M, Ellwood L. Effect of an activated charcoal product (DOAC StopTM) intended for extracting DOACs on various other APTT-prolonging anticoagulants. Clin Chem Lab Med 2019;57:690-66. 10. Favaloro EJ, Gilmore G, Arunachalam S, Mohammed S, Baker R. Neutralising rivaroxaban induced interference in laboratory testing for lupus anticoagulant (LA): A comparative study using DOAC Stop and andexanet alfa. Thromb Res. 2019;180:10-19.

20 Disclosures/Potential Conflicts of Interest

Disclosures:

Dorothy Adcock has received honoraria from Siemens Healthcare Diagnostics.

Robert Gosselin has provided expert testimony for dabigatran and rivaroxaban testing, has received honoraria from Siemens Healthcare Diagnostics, Machaon Laboratories and Diagnostica Stago, and serves as a consultant for Diagnostic Grifols and UniQure, and advisory board member for BioMarin.

21 Thank you for participating in this Clinical Chemistry Trainee Council Pearl of Laboratory Medicine.

Find our upcoming Pearls and other Trainee Council information at www.traineecouncil.org

Download the free Clinical Chemistry app on iTunes today for additional content!

Follow us:

22